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Abstract
Tumor necrosis factor-α (TNF) and toll-like receptors (TLR) are important mediators of 
inflammation. We examined 10 of these genes with respect to breast cancer risk and mortality in a 
genetically admixed population of Hispanic/Native American (NA) (2111 cases, 2597 controls) 
and non-Hispanic white (NHW) (1481 cases, 1585 controls) women. Additionally, we explored if 
diet and lifestyle factors modified associations with these genes. Overall, these genes 
(collectively) were associated with breast cancer risk among women with >70% NA ancestry 
(PARTP = 0.0008), with TLR1 rs7696175 being the primary risk contributor (OR 1.77, 95% CI 
1.25, 2.51). Overall, TLR1 rs7696175 (HR 1.40, 95% CI 1.03, 1.91; Padj=0.032), TLR4 rs5030728 
(HR 1.96, 95% CI 1.30, 2.95; Padj=0.014), and TNFRSF1A rs4149578 (HR 2.71, 95% CI 1.28, 
5.76; Padj=0.029) were associated with increased breast cancer mortality. We observed several 
statistically significant interactions after adjustment for multiple comparisons, including 
interactions between our dietary oxidative balance score and CD40LG and TNFSF1A; between 
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cigarette smoking and TLR1, TLR4, and TNF; between body mass index (BMI) among pre-
menopausal women and TRAF2; and between regular use of aspirin/non-steroidal anti-
inflammatory drugs and TLR3 and TRA2. In conclusion, our findings support a contributing role of 
certain TNF-α and TLR genes in both breast cancer risk and survival, particularly among women 
with higher NA ancestry. Diet and lifestyle factors appear to be important mediators of the breast 
cancer risk associated with these genes.
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Introduction
Tumor necrosis factor-α (TNF), a pro-inflammatory cytokine, stimulates cell proliferation 
and induces cell differentiation and is thought to be one of the most important promoters of 
inflammation. Additionally, TNF is a modulator of insulin resistance, especially among 
individuals who are obese or have chronic inflammation conditions; TNF has been reported 
to inhibit insulin-induced glucose uptake by targeting components of the insulin-signaling 
cascade [1–5]. TNF mediates cell survival and apoptosis through TNF receptors by 
activating at least two major signaling pathways, NFκB and the p38 mitogen-activated 
protein (MAP) kinase pathway. Tumor necrosis factor receptor superfamily member 1A 
(TNFRSF1A or TNFR1) is a major receptor for TNF-alpha that activates NFκB, mediates 
apoptosis, and functions as a regulator of inflammation. TNF receptor-associated factor 2 
(TRAF2) is a member of the TRAF protein family that interacts with TNF receptors. TRAF2 
is required for TNF activation of mitogen activated protein kinase 8 (MAPK8 alias JNK1) as 
well as NFκB and therefore is thought to influence the apoptotic effects of TNF. TNFSF10 
(TRAIL) protein expression has been elevated in adriamycin-treated breast cells [6]. This 
protein preferentially induces apoptosis in transformed and tumor cells. CD40LG, also 
known as TNFSF5 and TRAP, is involved in TNF-signaling pathway and related cytokine 
activity. Toll-like receptors (TLR) also are mediators of inflammation and potentially 
important modulators of cancer risk through their involvement in the NFκB-signaling 
pathway [7,8]. TLR4 specifically has been linked to breast cancer [9] and to colon tumor 
progression and metastatic potential [10,11]. TRAIL has been designated CD253 (cluster of 
differentiation 253); TLR2 has been designated as CD282; and TLR3 has been designated as 
CD283.
In this study we examine genetic variation in TLR and TNF-related genes as they relate to 
breast cancer risk and survival. TNF rs1800629 has been associated with breast cancer risk 
in a small case-control study of Mexican women [12], suggesting that this gene and possibly 
its related pathway are important for breast cancer risk in Latina women. We evaluate 
associations by genetic ancestry since breast cancer incidence rates differ between non-
Hispanic white (NHW), Hispanic, and Native American (NA) women living in the 
Southwestern United States [13]. We also evaluate associations by lifestyle factors that are 
associated with inflammation and insulin and could therefore modify risk associated with 
these genes and pathway. Factors we evaluate include dietary oxidative balance score 
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(DOBS) [14], body mass index (BMI), regular cigarette smoking, use of aspirin or other 
non-steroidal anti-inflammatory drugs (NSAIDs), and having been diagnosed with diabetes. 
Given the association of these genes with apoptosis and metastatic potential, we evaluate 
their association with breast cancer mortality.
Methods
The Breast Cancer Health Disparities Study includes participants from three population-
based case-control studies [13], the 4-Corners Breast Cancer Study (4-CBCS) [15], the 
Mexico Breast Cancer Study (MBCS)[16], and the San Francisco Bay Area Breast Cancer 
Study (SFBCS) [17,18], who completed an in-person interview and who had a blood or 
mouthwash sample available for DNA extraction. Information on exposures was collected 
up to the referent year, defined as the calendar year before diagnosis for cases or before 
selection into the study for controls. 4-CBCS participants were between 25 and 79 years; 
MBCS participants were between 28 and 74 years; and SFBCS participants were between 35 
to 79 years. All participants signed informed written consent prior to participation and each 
study was approved by their Institutional Review Board for Human Subjects.
Data Harmonization
Data were harmonized across all study centers and questionnaires as previously described 
[13]. Women were classified as either pre-menopausal or post-menopausal based on 
responses to questions on menstrual history. Pre-menopausal women were those who 
reported still having periods during the referent year (defined as the year before diagnosis 
for cases or before selection into the study for controls). Post-menopausal women were 
those who reported either a natural menopause or if they reported taking hormone therapy 
(HT) and were still having periods or were at or above the 95th percentile of age for those 
who reported having a natural menopause (i.e., ≥ 12 months since their last period). Women 
in 4-CBCS and SFBCS were asked to self-identify their race/ethnicity and were classified as 
non-Hispanic white (NHW), Hispanic, Native American (NA) or a combination of these 
groups. Women in MBCS were not asked their race or ethnicity.
Lifestyle variables included BMI calculated as self-reported weight (kg) during the referent 
year divided by measured height squared (m2) and categorized as normal (<25 kg/m2), 
overweight (25–29.9 kg/m2), and obese (≥30 kg/m2). Cigarette smoking was evaluated as 
current, former, or never a regular smoker, where regular was defined as having smoked one 
or more cigarettes for six months or longer in 4-CBCS and SFBCS (data available for a 
subset of subjects only) or having smoked 100 or more cigarettes in MCBCS. A dietary 
oxidative balance score (DOBS) that included nutrients with anti- or pro-oxidative balance 
properties was developed as previously reported [14]. Dietary information was collected via 
a computerized validated diet history questionnaire in 4-CBCS [19,20], a 104-item semi-
quantitative Food Frequency Questionnaire (FFQ) in MBCS [21], and a modified version of 
the Block Food Frequency Questionnaire in SFBCS [22]. Alcohol consumption was based 
on long-term use; consumption during the referent year was used for a subset of SFBCS 
women without information on long-term use. Regular use of aspirin or NSAIDS defined as 
three or more times a week for at least one month was available for the 4-CBCS only. A 
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history of diabetes was defined as ever being told by a health care provider that you had 
diabetes or high blood sugar (available only for a subset of SFBCS participants).
Genetic Data
DNA was extracted from either whole blood (n=7287) or mouthwash (n=634) samples. 
Whole Genome Amplification (WGA) was applied to the mouthwash-derived DNA samples 
prior to genotyping. A tagSNP approach was used to capture variation across the entire 
candidate genes. Genes were selected based on the literature available at the time the 
platform was developed that indicated a potential effect on inflammation. TagSNPs were 
selected using the following parameters: linkage disequilibrium (LD) blocks were defined 
using a Caucasian LD map in concordance with the custom-made GoldenGate chemistry 
array and an r2=0.8; minor allele frequency (MAF) >0.1; range= −1500 bps from the 
initiation codon to +1500 bps from the termination codon; and 1 SNP/LD bin. Additionally, 
104 Ancestry Informative Markers (AIMs) were used to distinguish European and NA 
ancestry [13]. All markers were genotyped using a multiplexed bead array assay format 
based on GoldenGate chemistry (Illumina, San Diego, California). A genotyping call rate of 
99.93% was attained (99.65% for WGA samples). We included 132 blinded internal 
replicates representing 1.6% of the sample set. The duplicate concordance rate was 99.996% 
as determined by 193,297 matching genotypes among sample pairs. In the current analysis 
we evaluated tagSNPs for CD40LG alias TNFSF5 and TRAP (3 SNPs), TLR1 (1 SNP), 
TLR2 (4 SNPs), TLR3 (4 SNPs), TLR4 (8 SNPs), TNF (2 SNPs on Illumina and 1 taqman), 
TNFRSF1A (4 SNPs), TNFRSF11A (25 SNPs), TNFSF10 (12 SNPs), and TRAF2 (4 SNPs). 
Online Supplement 1 provides a description of these genes and SNPs.
Tumor Characteristics and Survival
Data on estrogen receptor (ER) and progesterone receptor (PR) tumor status and survival 
were available for cases from 4-CBCS and SFBCS only. Cancer registries in Utah, 
Colorado, Arizona, New Mexico, and California provided information on stage at diagnosis, 
months of survival after diagnosis, cause of death, and ER and PR status. Surveillance 




The program STRUCTURE was used to estimate individual ancestry for each study 
participant assuming two founding populations [23,24]. A three-founding population model 
was assessed but did not fit the population structure. Participants were classified by level of 
percent NA ancestry (≤28%, >28–70%, and >70%), based on the distribution of genetic 
ancestry in the control population [13].
SNP Associations
Genes and SNPs were assessed for their association with breast cancer risk overall, by strata 
of genetic ancestry, and by menopausal status in the whole population and by ER/PR status 
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for the 4-CBCS and SFBCS. All statistical analyses were performed using SAS version 9.3 
(SAS Institute, Cary, NC). Logistic regression models were used to estimate odds ratios 
(OR) and 95% confidence intervals (CI) for breast cancer risk associated with SNPs. 
Confounding variables adjusted in these analyses were study, BMI in the referent year, and 
parity as a categorical variables and age (five-year categories) and genetic ancestry as 
continuous variables. A p value of <0.05 was considered statistically significant, although 
results are presented for those where the unadjusted p values was <0.05 and the multiple 
comparison adjusted p value was <0.15. Associations at this level are presented since group 
sample sizes vary and these associations could be relevant for replication in other 
populations. Associations with SNPs were assessed assuming a co-dominant model. Based 
on the initial assessment, SNPs that appeared to have a dominant or recessive mode of 
inheritance were evaluated with those inheritance models in subsequent analyses. For 
stratified analyses, the p value was based on the Wald chi-square test comparing the 
homozygote rare to the homozygote common when presenting the co-dominant model. Tests 
for interactions were evaluated using Wald one degree of freedom (1-df) tests. The 
multinomial p value reported for ER/PR status using the glogit link in the logistic procedure 
excludes controls. Adjustments for multiple comparisons within the gene used the step-
down Bonferroni correction, taking into account the degree of correlation of the SNPs 
within genes using the SNP spectral decomposition method proposed by Nyholt [25] and 
modified by Li and Ji [26].
Interactions
We assessed gene by environment interactions among environmental and lifestyle factors 
that could influence candidate genes given their potential involvement in inflammation, 
including BMI (separately for pre- and post-menopausal women), smoking (current, former, 
or never smokers), dietary oxidative balance score, and regular use of aspirin/NSAID (for 4-
CBCS participants only). The dietary oxidative balance score (DOBS) was based on each 
individual’s ranking of anti-oxidants (vitamin C, vitamin E, beta carotene (data for beta 
carotene were not available for MBCS), folic acid, and dietary fiber) and pro-oxidants 
(alcohol). Nutrients were evaluated as nutrient per 1000 calories and quartiles of intake and 
the DOBS were based on study-specific distributions. Alcohol consumption was classified 
into three levels: the top 25th percentile of consumption, all other drinkers, and non-drinkers. 
In creating the DOBS, participants were assigned values of zero for low levels (first quartile) 
of exposure to anti-oxidants or high exposure to pro-oxidants (fourth quartile), one for 
intermediate levels (second and third quartiles) of exposure, and two for high levels (fourth 
quartile) of exposure to anti-oxidants and low exposure (first quartile) to pro-oxidants.
Survival Analysis
Survival months were calculated based on month and year of diagnosis and month and year 
of death or last contact. Survival updates were received in the winter of 2013 which included 
complete survival surveillance through December of 2012. Associations between SNPs and 
breast cancer-specific mortality among cases with a first primary invasive breast cancer 
were evaluated using Cox proportional hazards models to obtain multivariate hazard ratios 
(HR) and 95% confidence intervals (CI) among all women and by genetic ancestry strata. 
Since survival data were not available for MBCS, the upper two ancestry strata were 
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combined to evaluate survival by genetic ancestry. Individuals were censored when they 
died of causes other than breast cancer or were lost to follow-up. We present Wald p values 
for all women and by ancestry strata based on the comparison between the homozygote rare 
and common genotypes using models adjusted for age, study, genetic ancestry, BMI, and 
SEER stage. Interactions between genetic variants and genetic ancestry with survival were 
assessed using p values from 1-df Wald chi-square tests.
ARTP Analysis
We used the adaptive rank truncated product (ARTP) method that utilizes a highly efficient 
permutation algorithm to determine the significance of association of each gene and of all 
genes combined with breast cancer risk by genetic ancestry and by ER/PR status. Case/
control status was permuted 10,000 times within R version 3.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria) and p values based on 1-df Wald chi-square tests 
were generated from logistic regression models. We also assessed associations with 
mortality using the ARTP method, permuting vital status and survival months together. 
Likelihood-ratio test p values were calculated from Cox proportional hazard models. We 
controlled the logistic and Cox models using the adjustment variables previously stated. We 
report both pathway and gene p values based on the ARTP method (PARTP) [27,28]. Since 
ARTP has not been developed to incorporate lifestyle factors when evaluating interactions, 
results for interactions were adjusted for multiple comparisons as described above.
Results
The majority of women were Hispanic/NA, post-menopausal, had ER+/PR+ tumors, and 
were diagnosed with local stage disease (Table 1). Among NHW women 21.4% had died, 
compared to 19.8% of Hispanic/NA women; 47.6% of deaths among NHW women were 
from breast cancer, compared to 55.9% of deaths among Hispanic/NA women. Among 
NHW women, 44.4 to 45.9% had a BMI of <25 kg/m2, compared to 17.6 to 23.5% among 
Hispanic/NA women.
Few genes and SNPs were significantly associated with breast cancer risk (Table 2, shows 
those with an adjusted p value of <0.15). TLR1, TLR2, and TNFRSF11A had the strongest 
association among women with the highest level of NA ancestry. Of the 25 SNPs evaluated 
for TNFRSF11A, five were associated with breast cancer risk among those with high NA 
ancestry. Of these, rs7237982 (ORGG 2.34, 95% CI 1.05, 5.21), rs17069845 (ORTC/CC 0.74, 
95% CI 0.57, 0.97), and rs8083511 (ORCC 1.74, 95% CI 1.12, 2.70) were significantly 
associated with breast cancer risk and the ORs were significantly different from those in 
other ancestry groups prior to adjustment for multiple comparisons (data not shown in 
table). CD40LG rs1126535 was significantly associated with breast cancer risk among those 
with low NA ancestry and CD40LG rs5939073 was associated with breast cancer risk 
among those with intermediate ancestry.
No differences in risk were identified by menopausal status (data not shown), and only two 
significant associations were identified by ER/PR phenotype (Table 3). TLR3 rs5743305 
was associated with ER−/PR+ tumors and TNFRSF1A rs4149578 was significantly 
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associated with ER−/PR− tumors. Both of these genes had statistically significant ARTP p 
values of 0.011 and 0.023, respectively.
Two of the three SNPs analyzed in CD40LG and one of four SNPs in TNFRSF1A 
significantly interacted with DOBS (Table 4). CD40LG homozygote variant was associated 
with increased risk of breast cancer only among those with low DOBS. For the homozygote 
common genotype of TNFRSF1A rs4149570, breast cancer risk decreased with increasing 
DOBS. TLR1, TLR4 (1 of 4 SNPs) and TNF (1 of 4 SNPs) interacted with cigarette smoking. 
TLR1 homozygote rare genotype significantly increased risk only among never-smokers; 
TLR4 rs111536898 rare allele decreased risk among never-smokers; TNF rs1800630 rare 
allele increased risk among current smokers only. Three of four SNPs in TRAF2 were 
associated with BMI among pre-menopausal women only. For these SNPs, the rare allele 
was associated with a reduced risk of breast cancer among obese women. Two SNPs of 
TLR3 interacted with aspirin/NSAIDs with the greatest effect among regular users. TRAF2 
rs4880073 also interacted with aspirin/NSAID use with the AA genotype reducing breast 
cancer risk among non-regular users. After adjustment for multiple comparisons, no 
significant interactions between having diabetes and any SNPs were observed.
TLR1 rs7696175, TRL4 rs5030728, TNRFSF1A rs4149578, TNFSF10 rs231985, rs3136597, 
and rs231983 were associated with breast cancer-specific mortality (Table 5). In all 
instances the rare genotype was associated with poorer survival. Associations with TLR1, 
TLR4, TNFRSF1A, and TNFRSF10 rs231985 were slightly stronger among those with 
greater NA ancestry; however, there were no statistically significant differences in mortality 
by NA ancestry. Associations with all-cause mortality were similar as those presented for 
breast cancer-specific mortality (data not shown) with a few exceptions; TLR1 rs7696175, 
TLR4 rs5030728, and TNFSF10 rs231985 were uniquely associated with breast cancer-
specific mortality. On the other hand, TLR4 rs10759932 was strongly associated with overall 
mortality (ORcc = 1.94, 95% CI 1.14, 3.32) but not with breast cancer-specific mortality 
(OR=0.93, 95% CI 0.70, 1.24).
Discussion
Major contributions of this paper are the identification of important diet and lifestyle factors 
that modify associations between breast cancer risk and TNF and TLR-related genes and 
SNPs and of the finding that variants in these genes are associated with both breast cancer 
risk and mortality in a genetically admixed population. However, few genes and SNPs were 
associated with either breast cancer risk or mortality. We confirmed that TLR1, which was 
previously identified in a breast cancer GWAS, was associated with breast cancer risk and 
mortality, especially among women with greater NA ancestry. Additionally, TLR4, 
TNFRSF1A, and TNFS10 were associated with breast cancer-specific mortality. TLR3 
rs5743305 was associated with ER−/PR+ tumors and TNFRSF1A rs4149578 was 
significantly associated with ER−/PR− tumors. Diet and lifestyle factors associated with 
oxidative stress, inflammation, and insulin significantly interacted with several SNPs in 
these genes.
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TLRs are a set of innate immunity genes involved in the activation of NFKB and MAPK, 
thereby mediating immune/inflammatory response [29]. TLRs can promote inflammation, 
cell survival and tumor progression [30]. Studies have shown associations between TLR4 
Asp299Gly (rs4986790) with increased breast cancer risk and lower metastasis-free 
survival, although TLR4 rs1927911 and rs10759932 were not associated with survival [31]. 
TLR4 rs4986970 affects the extracellular domain of TLR4 and is associated with reduced 
endotoxin responses [31]; TLR4 rs4986971 (in perfect LD with rs4986970) in the promoter 
region also has been shown to affect gene function [8]. Reduced expression of TLR4 has 
been shown to inhibit breast cancer cell proliferation; knock out of TLR4 gene can actively 
inhibit breast cancer cell survival [30]. TLR3 has been shown to directly trigger apoptosis in 
human breast cancer cells [30,32]. TLR1 was the only gene in this study associated with 
breast cancer risk based on the ARTP results while both TLR1 rs7696175 and TLR4 
rs5030728 were associated with breast cancer-specific mortality. We did not detect any 
significant associations with previously identified functional SNPs in either TLR4 or TNF. 
TLR1 rs7696175, which we and others have previously reported being associated with breast 
cancer risk [33,34], was identified as being a major contributor to risk within the pathway 
and also associated with mortality in this study.
The TNF family is a group of cytokines associated with apoptosis and antitumor activity; 
however, they also are involved in inflammation, immunity, and tumor progression [35]. A 
previous study in Mexico women found that TNF -308 G>A polymorphism (rs1800629) was 
associated with breast cancer risk [12]. We did not confirm this association. In our study the 
MAF was 0.079 among Hispanic controls, the majority of whom were from Mexico, while 
the MAF in NHWs was 0.17. The Mexico study was based on 294 controls (1% AA 
genotype) and 465 cases (14% AA genotype). Our data are in HWE and show 1 case and no 
controls with this genotype in the highest NA ancestry group (423 cases, 608 controls) that 
is predominately from Mexico; our numbers are consistent with allele frequencies reported 
for Hispanic populations in National Center for Biotechnology Information. A meta-analysis 
of this SNP and breast cancer risk showed a null association as we observed in this study 
[36].
TNF apoptosis inducing ligand (TNFSF10 or TRAIL) has been shown to activate apoptosis 
upon binding to its receptor and has been shown to influence survival among those with 
metastatic colon cancer [37–39]; it was associated with breast cancer-specific mortality in 
this study. Triple negative breast cancer cell lines have been shown to be sensitive to 
TNFSF10, whereas other tumor phenotypes are not [38,40]. While we did not see an 
association between any SNPs in this gene and ER−/PR− tumors, HER2 data were not 
available and we did observe an association between ER−/PR− tumors and TNFRSF1A 
(TNFR superfamily receptor 1A or p60). TNFRSF1A rs4149570 and rs12426675 have been 
associated with hepatocellular carcinoma cancer and these SNPs in the promoter have high 
transcriptional activity [41]. Functionality has been assigned to TNFRSF1A rs4149570 in the 
promoter that results in repression of TNFR1 [41]. We observed a significant interaction 
with DOBS and this SNP. TNFRSF1A rs4149578 was associated with breast cancer-specific 
mortality in our study.
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We examined several diet and lifestyle factors that could influence oxidative stress, the 
functional role of these genes. Two of the three SNPs analyzed in CD40LG and one of four 
SNPs in TNFRSF1A interacted significantly with DOBS, while TLR1 (1), TLR4 (1 of 4 
SNPs) and TNF (1 of 4 SNPs) interacted with cigarette smoking. CD40LG is an immune 
response gene and involved in thrombo-inflammatory reactions by up-regulating cell 
adhesion molecules and increased production of pro-inflammatory cytokines and reactive 
oxygen species [42,43]. Higher intake of dietary antioxidants modified the risk associated 
with the variant allele in two of the CD40LG SNPs. Vitamin C, which is a component of our 
DOBS, has been shown to suppress NFκB activation by inhibiting TNF activation of IKK 
[44]. TNF also has been shown to be able to induce reactive oxygen species [12]. Cigarette 
smoking has been shown to reduce innate immune response by suppressing inflammatory 
mediators [45], and a high oxidant/free radical burden in cigarette smoke has been correlated 
with increased expression of inflammatory mediator TNF [46]. The interaction we observed 
between TLRs and TNF and cigarette smoking has biological plausibility, given the 
influence of cigarette smoking on immune response and free radical burden and the key role 
of TLR and TNF in mediators of immune response.
Two SNPs of TLR3 interacted with aspirin/NSAIDs with the greatest effect found among 
regular users; TRAF2 rs4880073 also interacted with aspirin/NSAIDs. Aspirin has been 
shown to interfere with the NFκB complex [47]. TRAF2 is required for an NFκB 
independent signal that protects against TNF-induced apoptosis and TLR3 signaling 
activates the transcription of NFκB and interferon regulatory factor 3 [48]. TLR3 rs3775291 
has been associated with aspirin-exacerbated respiratory disease where eosinophils are 
activated via TLR3 and then recruit leukocytes to sites of inflammation as part of an 
inflammatory response.
Three of four SNPs in TRAF2 were associated with BMI among pre-menopausal women, 
but not among post-menopausal women. The immune system has been shown to play a role 
in obesity and insulin resistance. The CD40 signaling intermediary is TRAF2 and it has been 
shown that CD40-mice have worsened insulin resistance. Thus the CD40/TRAF2 signaling 
pathway is thought to protect against adipose tissue inflammation and metabolic 
complications associated with obesity [49].
This study represents one of the largest studies of breast cancer in Hispanics, a genetically 
admixed population of European and NA ancestry. The pooling of data from three studies 
allowed us to evaluate associations with risk, mortality, and lifestyle factors that could 
mediate genetic risk. We have pooled our populations to test the hypothesis that differences 
in risk are associated with ancestry, thus using the population only as a replication from one 
to the other could yield misleading results. While we have tried to target key genes and 
SNPs in the candidate pathway, there may be other important genes and SNPs that are not 
included here. We utilized the Illuminia platform that was based on a Caucasian population 
LD structure, which could result in not capturing the entire variation in populations with 
more NA ancestry. Likewise, since we used a tagSNP approach to capture variation across 
the gene, we have detected associations with SNPs that we do not know their functional 
significance. Other variables such as persistent infections or country of nativity might be 
important confounders which we were not able to adjust in our data. Although we used 
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several statistical methods to adjust for the associations observed among our candidate 
genes, associations could still be chance findings that need replication in other similar 
populations.
Several genes and SNPs were associated with breast cancer risk and mortality, although the 
pathway was only significant for women with the highest NA ancestry Additionally, DOBS, 
cigarette smoking, pre-menopausal BMI, and use of aspirin/NSAID significantly interacted 
with several SNPs within the pathway. This study suggests the importance of incorporating 
diet and lifestyle factors to obtain a better understanding of the total underlying genetic risk 
associated with breast cancer.
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• Associations were stronger among women with greater Native American 
ancestry.
• TLR1 rs7696175 had the strongest influence on risk.
• TLR1, TLR4, TNFRSF1A were associated with increased breast cancer 
mortality.
• Diet and lifestyle factors mediated breast cancer risk associated with these 
genes.
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